Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + orelabrutinib
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + orelabrutinib (Pola-RCHP-orelabrutinib) is an investigational chemoimmunotherapy combination regimen being evaluated for the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL), particularly the MCD genetic subtype (characterized by MYD88 and CD79B mutations). The regimen combines the Pola-R-CHP backbone—consisting of the CD79b-targeted antibody-drug conjugate polatuzumab vedotin (Polivy), the anti-CD20 monoclonal antibody rituximab, and the cytotoxic agents cyclophosphamide and doxorubicin—with orelabrutinib, a potent, highly selective, covalent Bruton's tyrosine kinase (BTK) inhibitor developed by InnoCare Pharma. This combination aims to provide enhanced efficacy in subtypes of DLBCL that are highly dependent on B-cell receptor (BCR) and MYD88 signaling pathways. It is currently being studied in Phase 2 clinical trials led by investigators such as Ou Bai.
- Other names
- Pola-R-CHP+orelabrutinib
02
Targets
CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)B-cell antigen receptor complex-associated protein beta chainTOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + orelabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + orelabrutinib.